SG11202106144VA - Compositions for the delivery of therapeutic agents and methods of use and making thereof - Google Patents

Compositions for the delivery of therapeutic agents and methods of use and making thereof

Info

Publication number
SG11202106144VA
SG11202106144VA SG11202106144VA SG11202106144VA SG11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA
Authority
SG
Singapore
Prior art keywords
delivery
compositions
making
methods
therapeutic agents
Prior art date
Application number
SG11202106144VA
Other languages
English (en)
Inventor
Brian R Sloat
Michael A Sandoval
Tyler B West
Original Assignee
Disruption Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disruption Labs Inc filed Critical Disruption Labs Inc
Publication of SG11202106144VA publication Critical patent/SG11202106144VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
SG11202106144VA 2018-12-11 2019-12-09 Compositions for the delivery of therapeutic agents and methods of use and making thereof SG11202106144VA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862778132P 2018-12-11 2018-12-11
US201962846474P 2019-05-10 2019-05-10
US201962857567P 2019-06-05 2019-06-05
US201962889824P 2019-08-21 2019-08-21
US201962916754P 2019-10-17 2019-10-17
PCT/US2019/065288 WO2020123407A1 (en) 2018-12-11 2019-12-09 Compositions for the delivery of therapeutic agents and methods of use and making thereof

Publications (1)

Publication Number Publication Date
SG11202106144VA true SG11202106144VA (en) 2021-07-29

Family

ID=71076135

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106144VA SG11202106144VA (en) 2018-12-11 2019-12-09 Compositions for the delivery of therapeutic agents and methods of use and making thereof

Country Status (12)

Country Link
US (3) US20210290562A1 (ko)
EP (2) EP4272731A3 (ko)
JP (2) JP7326445B2 (ko)
KR (1) KR20210114409A (ko)
CN (2) CN117695226A (ko)
AU (4) AU2019398117B2 (ko)
BR (1) BR112021011087A2 (ko)
CA (1) CA3119037A1 (ko)
IL (1) IL283840A (ko)
MX (1) MX2021006912A (ko)
SG (1) SG11202106144VA (ko)
WO (1) WO2020123407A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7326445B2 (ja) 2018-12-11 2023-08-15 ディスラプション・ラブズ・インコーポレイテッド 治療剤の送達のための組成物並びにその使用及び製造方法
EP3937915A4 (en) * 2019-03-13 2022-12-21 Milane, Michael NOVEL NANOFORMULATION OF CANNABIDIOL (CBD) AND OTHER CANNABINOIDS FOR THE TREATMENT OF SKIN DISEASES
WO2021046196A1 (en) * 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for cannabis extracts and terpenes
US20230233466A1 (en) * 2020-06-17 2023-07-27 Disruption Labs Inc. Compositions for supplementing products with therapeutic agents and methods of use thereof
US20220117890A1 (en) * 2020-10-21 2022-04-21 Corn Products Development, Inc. Cannabinoid emulsions
US20220266206A1 (en) * 2021-02-19 2022-08-25 Gaia Botanicals Llc Dba Bluebird Botanicals Formulation and process for manufacturing a heat stable oil-in-water emulsion for cannabis beverages in plastic bottles
WO2022174352A1 (en) * 2021-02-22 2022-08-25 Cardiol Therapeutics Inc. Injectable cannabinoid formulations
WO2022217103A1 (en) * 2021-04-08 2022-10-13 Disruption Labs, Inc. Compositions for supplementing products with therapeutic agents and methods of use thereof
CA3217973A1 (en) * 2021-05-03 2022-11-10 Donald L. Simmons Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof
IT202100023063A1 (it) * 2021-09-07 2023-03-07 Herbal Neurocare S R L Composizione a base di cannabidiolo per il trattamento dei disturbi neuropsichici, infiammatori e da dolore, nell’uomo e negli animali
WO2023067509A1 (en) * 2021-10-18 2023-04-27 Disruption Labs, Inc. Compositions for supplementing kombucha products with therapeutic agents and methods of making and use thereof
WO2023194953A1 (en) * 2022-04-08 2023-10-12 Disruption Labs, Inc. Compositions for supplementing products with therapeutic agents and methods of use thereof
CN114681340A (zh) * 2022-04-13 2022-07-01 肌赋萃生物科技(上海)有限公司 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法
WO2024031176A1 (en) * 2022-08-11 2024-02-15 Cardiol Therapeutics Inc. Stable injectable cannabidiol formulations
WO2024073849A1 (en) * 2022-10-07 2024-04-11 Canaquest Medical Corp. Composition for treating epilepsy

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180713A (en) 1985-09-27 1993-01-19 Liposome Technology, Inc. Stabilized liposome/amphotercin B composition and method
CA2142103C (en) 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
IT1289939B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
NZ511568A (en) 1998-11-12 2003-08-29 Frank G An inhalation system using lipids for the delivery of bioactive compounds
JP2003504321A (ja) 1999-07-08 2003-02-04 オーランド・ハン リポソーム被包カンナビノイドの肺送達
WO2001049268A1 (en) 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030096000A1 (en) 2001-05-31 2003-05-22 Solis Rosa Maria Encapsulation of nanosuspensions in liposomes and microspheres
US7544374B2 (en) 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
JP4555569B2 (ja) 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
FR2843023B1 (fr) 2002-07-30 2004-09-24 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques contenant du kombucha.
US8980310B2 (en) 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
EP1778298A4 (en) 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
WO2006024958A2 (en) 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
CA2581775A1 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
EP1855669A4 (en) 2005-01-28 2010-07-07 Bc Cancer Agency LIPOSOMAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF AGENTS
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US8898734B2 (en) 2005-08-20 2014-11-25 Riverbed Technology, Inc. Analyzing security compliance within a network
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007043057A2 (en) 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070116829A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company Pharmaceutical Composition with High-Potency Sweetener
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
ATE515260T1 (de) 2006-03-13 2011-07-15 Advanced In Vitro Cell Technologies S L Stabile nanokapselsysteme für die verabreichung von wirkstoffen
US7506600B2 (en) 2006-09-29 2009-03-24 Honda Motor Co., Ltd. Waterborne vehicle
WO2008144747A2 (en) 2007-05-21 2008-11-27 The Regents Of The University Of California Lipoproteins, lipopeptides and analogs, and methods for making and using them
US20080296639A1 (en) 2007-06-01 2008-12-04 Dalsa Corporation Semiconductor image sensor array device, apparatus comprising such a device and method for operating such a device
AU2009240470B8 (en) 2008-04-25 2015-02-05 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
JP5490795B2 (ja) 2008-07-15 2014-05-14 コムストック、ロバート・ローレンス 栄養補給組成物のための改善された乳化系
EP2370064A4 (en) 2008-12-11 2012-09-19 A P Pharma Inc METHOD FOR INCREASING THE STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS
EP2525782B1 (en) 2010-01-18 2019-03-13 Concept Medical Research Private Limited Formulations of nano-carriers and methods of preparing the same
WO2011092708A2 (en) 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
JP2013530223A (ja) 2010-07-01 2013-07-25 コバリス，インコーポレイテッド 集束音響を用いたナノ製剤を調製するための組成物および方法並びにナノ送達用のシステム
GB201019434D0 (en) 2010-11-17 2010-12-29 Isis Innovation Sonosensitive nanoparticles
MX364229B (es) 2011-02-04 2019-04-17 Infirst Healthcare Ltd Composiciones y metodos para tratar enfermedades cardiovasculares.
CN103702988A (zh) 2011-03-25 2014-04-02 3M创新有限公司 作为有机兰金循环工作流体的氟化环氧化物和使用其的方法
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
WO2013009928A1 (en) 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
CN102929871A (zh) 2011-08-08 2013-02-13 腾讯科技（深圳）有限公司 一种网页浏览方法、装置及移动终端
US20130138615A1 (en) 2011-11-29 2013-05-30 International Business Machines Corporation Synchronizing updates across cluster filesystems
WO2013105101A1 (en) 2012-01-13 2013-07-18 Department Of Biotechnology Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
SG11201500096YA (en) 2012-07-09 2015-02-27 Genentech Inc Immunoconjugates comprising anti - cd79b antibodies
EP2884962B1 (en) 2012-08-17 2019-05-01 Smartek International LLC Preparation of desiccated liposomes for use in compressible delivery systems
EP2934512B1 (en) 2012-12-18 2021-11-24 Kotzker Consulting LLC Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
US10801622B2 (en) 2013-04-18 2020-10-13 Bal Seal Engineering, Llc Interlocking face seal assemblies and related methods
KR101543507B1 (ko) 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
US9326967B2 (en) 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
US20150103850A1 (en) 2013-10-10 2015-04-16 Avago Technologies General Ip (Singapore) Pte. Ltd. Communication Device Utilizing An Interrupting Alignment Pattern
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
EP3062774A2 (en) 2013-10-31 2016-09-07 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2015117011A1 (en) 2014-01-31 2015-08-06 Pocket Tea, Llc Tea composition for oral administration
US9766473B1 (en) 2014-02-03 2017-09-19 Automation Engineering, Inc. Automated UV calibration, motorized optical target and automatic surface finder for optical alignment and assembly robot
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
US20170224634A1 (en) 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
IL302782A (en) 2014-05-29 2023-07-01 Radius Pharmaceuticals Inc Stable cannabinoid formulations
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20160367496A1 (en) 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
EP3193834B1 (en) 2014-09-18 2020-04-01 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
WO2016044805A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Soft gel compositions and pre-gel concentrates
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US20160081975A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Soft gel compositions and pre-gel concentrates
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US20180303791A1 (en) 2014-11-26 2018-10-25 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US20180289665A1 (en) 2014-12-07 2018-10-11 One World Cannabis Ltd Use of cannabis to treat migraine
WO2016100228A2 (en) 2014-12-15 2016-06-23 Nanosphere Health Sciences, Llc Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids
WO2016103254A1 (en) 2014-12-21 2016-06-30 One World Cannabis Ltd Use of cannabis to treat psoriasis
US20160184228A1 (en) * 2014-12-31 2016-06-30 Eric Morrison UNILAMELLAR NIOSOMES HAVING HIGH Kow PHARMACOLOGICAL COMPOUNDS SOLVATED THEREIN AND A METHOD FOR THE PREPARATION THEREOF
US20180000727A1 (en) 2015-01-21 2018-01-04 Michael Willinsky Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaer
AU2015385825A1 (en) * 2015-03-10 2017-10-05 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
AU2016231788A1 (en) * 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US20160287152A1 (en) 2015-03-30 2016-10-06 Verily Life Sciences Llc Functionalized Nanoparticles, Methods and In Vivo Diagnostic System
US9835558B2 (en) 2015-04-20 2017-12-05 Chunqiu Zhang Aggregation-induced emission luminogen having an peptide sequence and its uses thereof
CA2985969A1 (en) 2015-05-13 2016-11-17 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof
JP6899506B2 (ja) 2015-05-28 2021-07-07 フレッシュ・カット・ディベロップメント・エル・エル・シー 安定なカンナビノイド製剤
US20200121616A1 (en) * 2015-06-09 2020-04-23 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CA2988869A1 (en) 2015-06-11 2016-12-15 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (mm)
KR20160149398A (ko) 2015-06-18 2016-12-28 조셉 종을 정 비타민 c 전달 시스템 및 그 리포솜 조성물
CA2991911A1 (en) 2015-07-10 2017-01-19 University Of Vermont And State Agricultural College Methods and compositions to treat drug-induced diseases and conditions
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
EP3368014B1 (en) 2015-10-26 2023-10-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Novel cannabinoid formulations
CA3020798A1 (en) 2016-04-12 2017-10-19 Scott SCHANEVILLE Ingestible films having substances from hemp or cannabis
AU2017250001B2 (en) 2016-04-12 2017-12-14 Little Green Pharma Ltd Liposomal preparation and methods of treatment
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US20180255801A1 (en) 2016-05-27 2018-09-13 Pocket Tea, Llc Compositions containing tea, tea-like or other non-tobacco leaf-like material
EP3462885A4 (en) 2016-05-27 2020-01-22 Insys Development Company, Inc. STABLE CANNABINOID FORMULATIONS
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
WO2018054077A1 (en) 2016-09-26 2018-03-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Composition for treating ocular diseases and methods of usage and making
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
WO2018112479A1 (en) 2016-12-16 2018-06-21 Flavorsense Dried flakes with active ingredients
AU2018221739A1 (en) 2017-02-15 2019-08-29 Molecular Infusions, Llc Formulations
WO2018200024A1 (en) 2017-04-27 2018-11-01 Insys Development Company, Inc. Stable cannabinoid formulations
WO2018204326A1 (en) 2017-05-01 2018-11-08 Mj Wooly Corporation Methodology and formulation for creating a powder of an encapsulated cannabis-based component embedded in a polymer matrix
WO2018205038A1 (en) 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
EP3630067A4 (en) * 2017-05-26 2021-08-11 Altum Pharmaceuticals Inc. BIPHASIC CANNABINOID ADMINISTRATION
EP3417846A1 (en) 2017-06-19 2018-12-26 Gifar Srl Food and/or nutraceutical composition
WO2018237109A1 (en) 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
CN110996911B (zh) 2017-06-26 2023-01-17 福多兹制药公司 阿瑞匹坦的纳米微脂囊配制品及其方法和应用
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same
EP3735240A4 (en) 2018-01-03 2021-08-18 ICDPharma Ltd SOLID SELF-SYSTEMULATING CANNABINOID COMPOSITIONS
US20200330378A1 (en) 2018-01-03 2020-10-22 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
JP2021534822A (ja) * 2018-08-20 2021-12-16 ヘクソ・オペレーションズ・インコーポレイテッド 増強されたカンナビノイドプロファイルのユーザー経験を有するカンナビス注入製品
JP7326445B2 (ja) 2018-12-11 2023-08-15 ディスラプション・ラブズ・インコーポレイテッド 治療剤の送達のための組成物並びにその使用及び製造方法

Also Published As

Publication number Publication date
US20210251917A1 (en) 2021-08-19
AU2019398117A1 (en) 2021-04-08
CN113382719A (zh) 2021-09-10
EP3840730A1 (en) 2021-06-30
EP4272731A2 (en) 2023-11-08
BR112021011087A2 (pt) 2021-08-31
JP2023159144A (ja) 2023-10-31
MX2021006912A (es) 2021-08-24
AU2021203013C1 (en) 2023-08-10
AU2021203013A1 (en) 2021-06-10
US11260033B2 (en) 2022-03-01
AU2021203006A1 (en) 2021-06-10
AU2021203006B2 (en) 2023-06-08
EP4272731A3 (en) 2024-02-14
US20210290562A1 (en) 2021-09-23
CN117695226A (zh) 2024-03-15
KR20210114409A (ko) 2021-09-23
IL283840A (en) 2021-07-29
WO2020123407A1 (en) 2020-06-18
US20220241217A1 (en) 2022-08-04
AU2023210660A1 (en) 2023-08-24
JP2022512235A (ja) 2022-02-02
AU2021203013B2 (en) 2023-05-11
CA3119037A1 (en) 2020-06-18
CN113382719B (zh) 2023-10-31
EP3840730A4 (en) 2021-12-22
AU2019398117B2 (en) 2021-04-15
EP3840730B1 (en) 2023-09-20
JP7326445B2 (ja) 2023-08-15

Similar Documents

Publication Publication Date Title
IL283840A (en) Preparations for administering therapeutic substances and methods for their use and preparation
IL276464A (en) Methods and preparations for administering therapeutic protein
IL268999B (en) Compounds and preparations for intracellular administration of medicinal agents
PL3386484T3 (pl) Kompozycje i sposoby dostarczania środków terapeutycznych
IL273959A (en) Methods and preparations for the treatment of rare diseases
EP3813853A4 (en) DELIVERY COMPOSITIONS AND METHODS OF USE
EP3512554A4 (en) PLATE COMPOSITION AND METHOD FOR DISPENSING THERAPEUTIC AGENTS
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3740576A4 (en) THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
IL287796A (en) Preparations and methods for the treatment of diseases mediated by ATPase
SI3768284T1 (sl) Sestavki iz flagelina enterococcusa za uporabo v terapiji
EP3773654C0 (en) POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS
EP3773747A4 (en) USE OF EXOSOMES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
IL271596A (en) Preparations for administering drugs and methods of using them
PL3867282T3 (pl) Koniugaty kwasu hialuronowego i aminobisfosfonianów i ich zastosowanie terapeutyczne
EP3781194A4 (en) COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS
EP3856892A4 (en) COMPOSITIONS AND METHODS FOR IN SITU DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS
IL282671A (en) Therapeutic methods and compositions
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EP3773732A4 (en) METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF A THERAPEUTIC AGENT
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201813312D0 (en) Compounds and their therapeutic use